An integrated valuation model for payer and investor

BACKGROUND: In order to optimize positioning and associated drug price for both payer and investor, it is for a company essential to forecast the potential market access attractiveness for the new drug for different indications at the early onset of the clinical development program. This analysis mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuijten, Mark, Capri, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176355/
https://www.ncbi.nlm.nih.gov/pubmed/35693380
http://dx.doi.org/10.1080/20016689.2022.2080631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176355/
https://www.ncbi.nlm.nih.gov/pubmed/35693380
http://dx.doi.org/10.1080/20016689.2022.2080631

Ejemplares similares